mTOR is activated in the majority of malignant melanomas
- PMID: 17914450
- DOI: 10.1038/sj.jid.5701074
mTOR is activated in the majority of malignant melanomas
Abstract
The objective of this study was to determine whether activation of the kinase mammalian target of rapamycin (mTOR) is associated with human melanoma. We found moderate or strong hyperphosphorylation of ribosomal protein S6 in 78/107 melanomas (73%). In contrast, only 3/67 benign nevi (4%) were moderately positive, and none were strongly positive. These data indicate that mTOR activation is very strongly associated with malignant, compared to benign, melanocytic lesions. Next, we tested six melanoma-derived cell lines for evidence of mTOR dysregulation. Five of the six lines showed persistent phosphorylation of S6 after 18 hours of serum deprivation, and four had S6 phosphorylation after 30 minutes of amino-acid withdrawal, indicating inappropriate mTOR activation. The proliferation of three melanoma-derived lines was blocked by the mTOR inhibitor rapamycin, indicating that mTOR activation is a growth-promoting factor in melanoma-derived cells. mTOR is directly activated by the small guanosine triphosphatase Ras homolog enriched in brain (Rheb), in a farnesylation-dependent manner. Therefore, to investigate the mechanism of mTOR activation, we used the farnesyl transferase inhibitor FTI-277, which partially blocked the growth of three of the six melanoma cell lines. Together, these data implicate activation of mTOR in the pathogenesis of melanoma, and suggest that Rheb and mTOR may be targets for melanoma therapy.
Similar articles
-
[Melanoma and cancer emergence in persons of 20-60 years against normal quantity of cambial cells in morphofunctional zones].Adv Gerontol. 2014;27(4):753-7. Adv Gerontol. 2014. PMID: 25946855 Review. Russian.
-
Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma.Melanoma Res. 2010 Apr;20(2):107-17. doi: 10.1097/CMR.0b013e32832ccd09. Melanoma Res. 2010. PMID: 20173664
-
The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.Invest Ophthalmol Vis Sci. 2010 Jan;51(1):421-9. doi: 10.1167/iovs.09-3974. Epub 2009 Aug 6. Invest Ophthalmol Vis Sci. 2010. PMID: 19661225
-
Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.Oncogene. 2007 Aug 16;26(38):5606-14. doi: 10.1038/sj.onc.1210346. Epub 2007 Mar 12. Oncogene. 2007. PMID: 17353907
-
Estrogen-induced activation of mammalian target of rapamycin is mediated via tuberin and the small GTPase Ras homologue enriched in brain.Cancer Res. 2006 Oct 1;66(19):9461-6. doi: 10.1158/0008-5472.CAN-06-1895. Cancer Res. 2006. PMID: 17018601
Cited by
-
mTOR hyperactivity and RICTOR amplification as targets for personalized treatments in malignancies.Pathol Oncol Res. 2024 Mar 7;30:1611643. doi: 10.3389/pore.2024.1611643. eCollection 2024. Pathol Oncol Res. 2024. PMID: 38515456 Free PMC article. Review.
-
CD133-Dependent Activation of Phosphoinositide 3-Kinase /AKT/Mammalian Target of Rapamycin Signaling in Melanoma Progression and Drug Resistance.Cells. 2024 Jan 26;13(3):240. doi: 10.3390/cells13030240. Cells. 2024. PMID: 38334632 Free PMC article. Review.
-
Genetic Silencing of AKT Induces Melanoma Cell Death via mTOR Suppression.Mol Cancer Ther. 2024 Mar 4;23(3):301-315. doi: 10.1158/1535-7163.MCT-23-0474. Mol Cancer Ther. 2024. PMID: 37931033
-
Advances in targeted therapy and immunotherapy for melanoma (Review).Exp Ther Med. 2023 Jul 13;26(3):416. doi: 10.3892/etm.2023.12115. eCollection 2023 Sep. Exp Ther Med. 2023. PMID: 37559935 Free PMC article. Review.
-
Canine melanoma: A review of diagnostics and comparative mechanisms of disease and immunotolerance in the era of the immunotherapies.Front Vet Sci. 2023 Jan 6;9:1046636. doi: 10.3389/fvets.2022.1046636. eCollection 2022. Front Vet Sci. 2023. PMID: 36686160 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous